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491Abstracts
OBJECTIVE: To estimate cost-effectiveness of pathogen
inactivation for platelet transfusions in Dutch cardiac
surgery. We used decision-tree analysis to evaluate the
cost-effectiveness of the addition of pathogen inactivation
of pooled platelets to standard procedures for platelet
transfusion safety (such as, donor recruitment and screen-
ing). METHODS: Data on transfusions were derived
from the University Hospital Groningen (Netherlands)
for 1997. Characteristics of platelet recipients (age,
gender, survival) and data/assumptions on viral and bac-
terial risks were linked to direct and indirect costs/bene-
ﬁts of pathogen inactivation. Post-transfusion survival
was simulated with a Markov-model. Standard methods
for cost-effectiveness were used. Cost-effectiveness was
expressed in net costs per life-year gained and estimated
in baseline-, sensitivity- and scenario analysis. Sensitivity
was analysed with respect to viral risks, discard rate and
discounting. Stochastic sensitivity analysis was performed
on bacterial risks. Scenario analysis was elaborated on
judicial aspects and occurrence of a new yet unknown
virus. RESULTS: Net costs per life-year gained were
€110,000 in the baseline (90% CI: €80,000–€180,000).
Sensitivity analysis revealed that cost-effectiveness was
insensitive to viral risks, but highly sensitive to, for
example, the assumed reduction in the discard rate and
discounting of life-years gained. Sensitivity and scenario
analysis showed potential reductions in cost-effectiveness
down to €50,000 per life-year gained. CONCLUSIONS:
Given relatively high net costs per life-year gained that
are internationally accepted for blood transfusion safety
interventions, our estimated cost-effectiveness ﬁgures for
pathogen inactivation may reﬂect acceptable cost-
effectiveness in this speciﬁc area. Validation of several
crucial parameters is required, in particular the Dutch risk
for acquiring transfusion-related sepsis. Further work
should extend the model to other countries, other patient
groups (haematology) and the potential elimination of
donor testing if pathogen inactivation is to cover the
whole spectra of pathogens and blood products.
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OBJECTIVES: Determine patient costs after stroke and
compare costs between regular care for stroke patients
and care organised in stroke services. METHODS:
Patient costs after stroke were calculated within the
framework of the evaluation of three experiments with
stroke services in the Netherlands. Total costs of care per
patient for the 6-month follow up were based on medical
consumption of 598 patients in 6 regions consecutively
admitted to a hospital after stroke. Care consumption and
cost data were collected for hospital, rehabilitation,
nursing home, and home care. Care consumption was
retrieved from patients’ medical records and from patient
interviews two and six months after stroke. Unit cost data
were collected at participating institutions. RESULTS: We
found that the total costs of care per patient for the 6
month follow up after stroke amount to almost €16,000
on average. Costs are dominated by institutional costs
and accommodation costs. Patients who die during the
acute phase incur less costs. For patients that survive the
acute phase, severity of disability, age, gender and place
of residence before stroke are the most important deter-
minants of costs, as they inﬂuence patients’ stroke careers.
These determinants of costs also interact. CONCLU-
SIONS: Stroke care organised in stroke service experi-
ments potentially is more effective than regular care,
although large differences in costs were found between
the three stroke services. The most efﬁcient stroke service
experiment was the one that was most successful in co-
ordinating patient ﬂow from hospital to (nursing) home,
through capacity planning and efﬁcient discharge proce-
dures. The other experiments suffered from waiting lists
for (nursing) home care, leading to “blocked beds” and
higher costs of care. The relations found between costs,
organisation of care, patient characteristics and disease
severity may be applied as building-blocks for DRGs for
stroke care.
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OBJECTIVE: The study aims to 1) estimate the costs of
hospital treatmetn and the value of lost production due
to early death associated with underweight, overweight
and obese patients, and to extrapolate the ﬁndings to
national costs and 2) estimate the potential beneﬁts of an
obesity intervention program in terms of cost-offsets.
METHODS: For the ﬁrst aim we use a retrospective
analysis of the hospital treatment episodes of a deﬁned
population with data obtained from screening of 33,196
middle-aged subjects living in Malmo, Sweden and col-
lected during a 15-year follow-up period. For the second
aim we apply a prospective cost analysis within a model-
ing framework. RESULTS: The yearly excess hospital
(somatic, psychiatric) care cost (SEK) for overweight (25-
BMI-29kg/sqm) and obesity (BMI 30kg/sqm and above)
was estimated to SEK 1300 million (US$130 million,
assuming $1 = SEK10), or about 2.3 percent of total hos-
pital care costs in Sweden. Indirect costs due to early mor-
tality for obese subjects were estimated to SEK 1200
million (US$120 million). For males at age 55+ the poten-
tial hospital costs savings, excluding costs of intervention,
that could be gained by an intervention that successfully
and sefely could alter the weight of an overweight or
obese individual to become normal weight was estimated
to SEK 30,000 (US$3,000) over 15 years. CONCLU-
SION: Hospital treatment costs are found to have a J-
